Advertisement
DHR vs RGEN
Which Stock Would AI Choose? Danaher Corporation (DHR) vs. Repligen Corporation (RGEN) Stock Comparison
Key Takeaways
- Danaher Corporation (DHR), a diversified life sciences giant, boasts a market cap of approximately $138 billion and a lower price-to-earnings (P/E) ratio of 39, signaling relative value compared to Repligen's (RGEN) smaller $7.4 billion cap and elevated P/E of 153.
- Year-to-date (YTD), RGEN has outperformed with +19.45% gains versus DHR's +14.42%, reflecting stronger short-term momentum in bioprocessing demand.
- DHR exhibits lower volatility with a beta of 0.99, contrasting RGEN's 1.19, appealing to stability-focused investors.
- Recent DHR Q1 earnings beat EPS expectations at $2.06 but missed revenue at $5.95 billion, while RGEN shows long-term growth potential amid biopharma recovery.
- Analysts rate DHR a Strong Buy with a $256 target, higher conviction than RGEN's Hold consensus around $181.
Introduction
Danaher Corporation (DHR) and Repligen Corporation (RGEN) operate in the life sciences tools and services sector, particularly bioprocessing, amid recovering biopharmaceutical demand. This comparison suits traders eyeing healthcare momentum and investors assessing growth versus stability trade-offs. With biopharma capacity expansions driving sector tailwinds, evaluating recent performance, valuations, and risk profiles helps inform relative positioning in today's market environment.
DHR Overview and Recent Performance
Danaher Corporation (DHR) is a global conglomerate spanning life sciences, diagnostics, and environmental applied solutions, with key exposure to bioprocessing equipment and consumables. Trading around $195.50 recently, the stock sits within its 52-week range of $180-$243, supported by a market cap exceeding $138 billion. In recent market activity, DHR delivered Q1 adjusted earnings per share (EPS) of $2.06, surpassing estimates, though revenue of $5.95 billion slightly missed expectations amid softer bioprocessing orders. YTD gains stand at +14%, bolstered by diversified revenue streams, but sentiment reflects caution on near-term growth moderation in biotech tools. Analyst upgrades persist, underscoring long-term innovation catalysts.
RGEN Overview and Recent Performance
Repligen Corporation (RGEN) specializes in bioprocessing technologies, including filtration and chromatography products essential for biologics manufacturing. The stock hovers near $132, within a 52-week band of $110-$176, with a $7.4 billion market cap. Recent weeks have seen upward momentum, with YTD performance at +19% driven by biopharma recovery signals and undervaluation narratives. Analyst commentary highlights durable growth from capacity expansions, though high P/E reflects premium pricing. Trading volume and options activity suggest potential volatility, influenced by sector peers and broader biotech sentiment shifts.
Trending AI Robots
Tickeron’s Trending AI Robots page spotlights 25 top-performing AI trading bots curated from over 350 available, each deploying machine learning for real-time signals across stocks, ETFs, and crypto. These bots showcase impressive stats, including annualized returns from +15% to +168%, win rates of 54%-88%, and profit factors up to 11.7, with strategies spanning swing trades, trend following, and paired long/short plays on sectors like semiconductors and precious metals. Timeframes vary from 1-day scalps to 55-day holds, often outperforming the S&P 500 in volatile conditions. Tailored for current markets, they offer risk-managed copy trading without minimum balances for signals. Explore these bots to align with your trading style.
Head-to-Head Comparison
Danaher’s (DHR) diversified business model across diagnostics and life sciences contrasts Repligen’s (RGEN) niche focus on bioprocessing consumables, exposing RGEN more directly to biologics cycles. Growth drivers overlap in biopharma expansion, but DHR benefits from broader end-markets. Recent momentum favors RGEN with superior YTD returns, yet DHR shows trend consistency post-earnings. Risk factors include RGEN’s higher beta (1.19 vs. 0.99) and valuation stretch, amplifying downside in slowdowns. Sector exposure ties both to healthcare, but market sentiment leans toward DHR’s scale and analyst backing.
Tickeron AI Verdict
Tickeron’s AI would currently favor Danaher Corporation (DHR) over Repligen Corporation (RGEN), prioritizing its relative stability, lower valuation multiples, Strong Buy analyst consensus, and diversified positioning amid bioprocessing uncertainties. While RGEN offers higher short-term upside potential, DHR aligns better with consistent trends and reduced volatility risks.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DHR is a Hold and RGEN is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
DHR’s FA Score shows that 1 FA rating(s) are green whileRGEN’s FA Score has 0 green FA rating(s).
- DHR’s FA Score: 1 green, 4 red.
- RGEN’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
DHR’s TA Score shows that 5 TA indicator(s) are bullish while RGEN’s TA Score has 6 bullish TA indicator(s).
- DHR’s TA Score: 5 bullish, 5 bearish.
- RGEN’s TA Score: 6 bullish, 3 bearish.
Price Growth
DHR (@Medical Specialties) experienced а -1.61% price change this week, while RGEN (@Pharmaceuticals: Other) price change was -3.21% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +0.70%. For the same industry, the average monthly price growth was +2.77%, and the average quarterly price growth was -3.13%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -1.83%. For the same industry, the average monthly price growth was -0.55%, and the average quarterly price growth was -14.44%.
Reported Earning Dates
DHR is expected to report earnings on Jul 28, 2026.
RGEN is expected to report earnings on Aug 04, 2026.
Industries' Descriptions
@Medical Specialties (+0.70% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Pharmaceuticals: Other (-1.83% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| DHR | RGEN | DHR / RGEN | |
| Capitalization | 126B | 7.15B | 1,763% |
| EBITDA | 7.08B | 176M | 4,022% |
| Gain YTD | -21.995 | -22.696 | 97% |
| P/E Ratio | 34.53 | 139.20 | 25% |
| Revenue | 24.8B | 763M | 3,250% |
| Total Cash | 5.7B | 785M | 726% |
| Total Debt | 18.5B | 688M | 2,689% |
DHR | RGEN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 81 | 39 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 10 Undervalued | 86 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 80 | 90 | |
PRICE GROWTH RATING 1..100 | 60 | 46 | |
P/E GROWTH RATING 1..100 | 60 | 100 | |
SEASONALITY SCORE 1..100 | 30 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
DHR's Valuation (10) in the Medical Specialties industry is significantly better than the same rating for RGEN (86) in the Biotechnology industry. This means that DHR’s stock grew significantly faster than RGEN’s over the last 12 months.
DHR's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as RGEN (100) in the Biotechnology industry. This means that DHR’s stock grew similarly to RGEN’s over the last 12 months.
DHR's SMR Rating (80) in the Medical Specialties industry is in the same range as RGEN (90) in the Biotechnology industry. This means that DHR’s stock grew similarly to RGEN’s over the last 12 months.
RGEN's Price Growth Rating (46) in the Biotechnology industry is in the same range as DHR (60) in the Medical Specialties industry. This means that RGEN’s stock grew similarly to DHR’s over the last 12 months.
DHR's P/E Growth Rating (60) in the Medical Specialties industry is somewhat better than the same rating for RGEN (100) in the Biotechnology industry. This means that DHR’s stock grew somewhat faster than RGEN’s over the last 12 months.
| DHR | RGEN | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 56% | 2 days ago 80% |
| Stochastic ODDS (%) | 2 days ago 56% | 2 days ago 82% |
| Momentum ODDS (%) | 2 days ago 62% | 2 days ago 73% |
| MACD ODDS (%) | 2 days ago 67% | 2 days ago 78% |
| TrendWeek ODDS (%) | 2 days ago 64% | 2 days ago 80% |
| TrendMonth ODDS (%) | 2 days ago 54% | 2 days ago 71% |
| Advances ODDS (%) | 8 days ago 54% | 8 days ago 74% |
| Declines ODDS (%) | 6 days ago 60% | 2 days ago 81% |
| BollingerBands ODDS (%) | 2 days ago 65% | N/A |
| Aroon ODDS (%) | 2 days ago 50% | 2 days ago 77% |
Advertisement
DHR and
Correlation & Price change
A.I.dvisor indicates that over the last year, DHR has been closely correlated with TMO. These tickers have moved in lockstep 77% of the time. This A.I.-generated data suggests there is a high statistical probability that if DHR jumps, then TMO could also see price increases.
| Ticker / NAME | Correlation To DHR | 1D Price Change % | ||
|---|---|---|---|---|
| DHR | 100% | +0.58% | ||
| TMO - DHR | 77% Closely correlated | -0.13% | ||
| A - DHR | 73% Closely correlated | -0.45% | ||
| RGEN - DHR | 68% Closely correlated | -4.05% | ||
| RVTY - DHR | 64% Loosely correlated | -0.96% | ||
| BIO - DHR | 64% Loosely correlated | -0.47% | ||
More | ||||
RGEN and
Correlation & Price change
A.I.dvisor indicates that over the last year, RGEN has been closely correlated with DHR. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if RGEN jumps, then DHR could also see price increases.
| Ticker / NAME | Correlation To RGEN | 1D Price Change % | ||
|---|---|---|---|---|
| RGEN | 100% | -4.05% | ||
| DHR - RGEN | 67% Closely correlated | +0.58% | ||
| A - RGEN | 65% Loosely correlated | -0.45% | ||
| BIO - RGEN | 60% Loosely correlated | -0.47% | ||
| MTD - RGEN | 59% Loosely correlated | +1.68% | ||
| TMO - RGEN | 58% Loosely correlated | -0.13% | ||
More | ||||